What We Do

We support our clients on a fee-for-service and/or success basis

What Our Clients Say About Us

Act as an external business development and licensing resource for life science clients

Provide clients with comprehensive industry experience and a large network of contacts

Support life science companies and investors in their BD&L and M&A activities

Create value by negotiating sustainable collaborations and partnership deals for clients

Coach management teams in their fund raising and transaction processes

Help clients to structure and negotiate necessary agreements to grow their business

Provide interim management and BOD support of VC-funded life science companies

Invest in very exciting and select early stage life science opportunities

What Our Clients And Transaction Partners Say About Us

„Incredibly dedicated, professional and effective deal making. You have made 'Mission Impossible' possible! Thank you!“

Chief Executive Officer, Biotech Client

„I have been very impressed by your leadership, your agility and your in-depth knowledge of the multiple dimensions that a deal like this one encompasses.“

Vice President, Head of Discovery, Big Pharma Transaction Partner of Client

„It was a masterpiece on how to successfully negotiate a deal. Elmar’s skills, his ability to build trust and his understanding of the entire deal, its implications for the client and his significant commitment were essential to get the deal done.“

Senior Partner International Law Firm, External Counsel of Client

„I have observed the same professional spirit at both sides of the table and you as a lead - Elmar - were truly impressive.“

Senior Vice President, General Counsel, Head of Business Development, Big Pharma Transaction Partner of Client

„Thanks a lot Elmar for your excellent support throughout this process. You created a lot of value for us, so thank you so much for that.“

Chief Executive Officer, Biotech Client

Select Deals

that Elmar supported, was involved in and/or negotiated

Collaboration and Licensing Deals

Licensing agreement of biotech client with major pharma company in field of prophylactic vaccines for infectious diseases with €400 million upfront payment and additional potential milestone payments up to €1.05 billion, plus royalties in the high single to low teens range
Collaboration and licensing agreement with major pharma company in field of prophylactic vaccines and monoclonal antibodies for infectious diseases with very significant upfront payment, FTE funding, milestones (total >$1.1 billion) and royalties - resulting in $300 million cash upfront for our biotech client
Co-development and licensing agreement with major pharma company for second generation multi-variant Covid-19 vaccine candidate of our biotech client - resulting in €150 million cash upfront and near-term milestones in addition to further opt-in payments from partner to our biotech client
Global collaboration, option and service agreement for Phase 3 Covid-19 vaccine candidate of our biotech client with a major pharma company - incl. supply chain support for several hundred million vaccine doses of our biotech client
Broad drug discovery alliance and technology licensing deal with pharma company with significant upfront payments, FTE funding, technology transfer fees, milestones and royalties - resulting in $120 million cash commitment from partner
Co-development and licensing agreement with US based biotech for commercial rights to clinical phase III compound in Europe, Middle East, Australia & New Zealand with significant upfront payment, FTE funding, milestones and significant royalties - resulting in >$60 million cash commitment from partner
Co-development and licensing agreement with Japanese pharma for commercial rights to clinical phase III compound in Japan with upfront payment, FTE funding, milestones and significant royalties - resulting in double digit million-dollar cash commitment from partner

Collaboration and Licensing Deals (continued)

Collaboration and licensing agreement with pharma company for commercial rights to clinical phase I oncology compound with significant upfront payment (€35 million), FTE funding, milestones (€430 million) and royalties
Collaboration, option and licensing agreement with pharma company for small molecule inhibitors in oncology field with upfront payment, FTE funding, option exercise payments, milestones and royalties
Strategic partnership of our biotech client with commercial vaccine company for the development, manufacturing and commercialization of a Shigella vaccine with upfront, milestone and low double digit royalty payments
Collaboration, option and licensing agreements with pharma company in field of prophylactic and therapeutic vaccines for infectious diseases with upfront payment, FTE funding, milestones and royalties
Collaboration, option and licensing agreement with pharma company in field of therapeutic cancer vaccines with upfront payment, FTE funding, milestones and royalties
Collaboration, option and licensing agreements with non-governmental agency in field of prophylactic and therapeutic vaccines for infectious diseases with FTE funding and milestones
Target discovery and drug discovery alliances with pharma and biotech companies in anti-bacterial field with upfront payment, FTE funding, milestones and royalties
Target and drug discovery alliance with pharma company in Osteoarthritis with upfront payment, FTE funding, milestones and royalties
Several collaboration and licensing agreements with biotechs in the US and Europe to discover and develop antibodies using various technology platforms for select targets
Target and drug discovery alliance with pharma company in Virology field with upfront payment, FTE funding, milestones and royalties
Collaboration, option and licensing agreements with north-American biotech to discover and develop delivery vehicles for nucleic acid based therapeutics and provide for technology access for our biotech client

M&A and Asset Divestment Transactions

Transatlantic M&A transaction with share-based acquisition of drug discovery company in United States
Take-over of biotech company based on asset acquisition - raised €8.7M as part of transaction
Corporate strategy consulting leading to later acquisition of private biotech company by US based company (up to $250 million, with undisclosed double digit million dollar upfront)
Trade sale of private biotech company to public biotech company (>€30 million in cash and shares upfront)
Trade sale of private biotech company to public biotech company (for double digit million Euro figure)

IP Licensing Deals

In-licensing of preclinical oncology compound from US Biotech
In-licensing of clinical phase II oncology compound from US University
In-licensing of clinical phase III oncology compound from US Pharma
In-licensing of drug discovery IP from US Biotech
In-licensing of technology, target and compound IP from several German Research Institutions
Out-licensing of preclinical anti-bacterial programs to European Biotech
Out-licensing of preclinical auto-immune program to European Biotech
Out-licensing of phase I oncology compound to European Pharma
Out-licensing of phase III oncology compound to US Biotech
Out-licensing of phase III oncology compound to Japanese Pharma

Financing Rounds

€40 million Series A round of biotech company (2016)
€80 million Series C round of biotech company (2012)
€27.6 million Series B round of biotech company (2010)
€104 million total equity investment in 3 private placements (2001, 2006, 2007)
€78.6 million follow-on offering with Nasdaq listing (June 2004)
€118.6 million IPO in Frankfurt – largest biotech IPO in Germany at the time (May 2000)
€20 million Series B round of biotech company (1999)
€8.4 million Series A round of biotech company (1997)

Other Transactions

Co-promotion agreements with pharma companies
Several manufacturing and supply agreements for cell lines and various monoclonal antibodies
Clinical trial supply agreements with pharma companies
Quality assurance agreements with pharma companies and manufacturing companies
Master service agreements with many CROs worldwide
MTAs with pharma, biotech and academic tech transfer organizations worldwide
Sponsored research agreements with universities
CDAs with many parties worldwide
Licensing and tech transfer agreements with universities and research institutes
Consulting agreements with many parties worldwide
Rental agreements, employment agreements, etc.

Site Notice

Information pursuant to § 5 TMG: EM Biotech GmbH, Starnberger Strasse 101b, 82069 Schäftlarn, Handelsregister: HRB 177319, Registration court: München

Represented by the Managing Director: Dr. Elmar Maier, Phone: +49 (0)8178 6090634, E-mail: info[at]em-biotech.com

Imprint

Domain Owner and Website Design by Dr. Elmar Maier, Starnberger Strasse 101b, 82069 Schäftlarn

Photo on Home Page by Hassan Pasha from Unsplash.com

Welcome